Program
HDAC Class I/IIb Inhibitor HG146
Its studies are mostly in Carcinoma, Adenoid Cystic · Lymphoma · Multiple Myeloma, led by HitGen.
Furthest: phase 2, since Jan 6, 20253 company-led studies, 1 open or runningNext primary completion: Dec 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HitGen | 31 open or running | phase 2since Jan 6, 2025 | Sep 29, 2018 | Dec 31, 2028phase 2 · NCT06781567 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 29, 2018First study: phase 1 study in Multiple MyelomaFirst studyNCT03710915 · 3 enrolled · China
- Jul 12, 2021Phase 1 study in LymphomaNCT04977167 · 24 enrolled · China
- Jan 6, 2025Phase 2 study in Carcinoma, Adenoid CysticNCT06781567 · 140 planned · China
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Carcinoma, Adenoid CysticNCT06781567
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06781567Carcinoma, Adenoid Cystic · China | 2 | Recruiting | Dec 31, 2028 | 140 |
| NCT04977167Lymphoma · China | 1 | Completed | Jun 13, 2024 | 24 |
| NCT03710915Multiple Myeloma · China | 1 | Terminated | Sep 28, 2022 | 3 |
How it is read
Names in the registry
- “HG146”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Adenoid Cystic, 1 study
- Lymphoma, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.